Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Inventory (2022 - 2025)

Historic Inventory for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $459000.0.

  • BioXcel Therapeutics' Inventory fell 6990.16% to $459000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $459000.0, marking a year-over-year decrease of 6990.16%. This contributed to the annual value of $679000.0 for FY2024, which is 6589.65% down from last year.
  • As of Q3 2025, BioXcel Therapeutics' Inventory stood at $459000.0, which was down 6990.16% from $506000.0 recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Inventory peaked at $2.7 million during Q2 2024, and registered a low of $459000.0 during Q3 2025.
  • Its 4-year average for Inventory is $1.5 million, with a median of $1.5 million in 2024.
  • In the last 5 years, BioXcel Therapeutics' Inventory skyrocketed by 18621.7% in 2023 and then tumbled by 8111.94% in 2025.
  • BioXcel Therapeutics' Inventory (Quarter) stood at $2.0 million in 2022, then increased by 0.3% to $2.0 million in 2023, then plummeted by 65.9% to $679000.0 in 2024, then plummeted by 32.4% to $459000.0 in 2025.
  • Its Inventory stands at $459000.0 for Q3 2025, versus $506000.0 for Q2 2025 and $642000.0 for Q1 2025.